← 返回

基于双特异性 TCR 分子的成熟化哺乳动物展示平台

英文原题:Mammalian Display Platform for the Maturation of Bispecific TCR-Based Molecules.

查看英文原题

Mammalian Display Platform for the Maturation of Bispecific TCR-Based Molecules.

PubMed 2022/05/10(内容时间) Antibodies (Basel) Q3 · IF 3.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

基于双特异性T细胞受体(TCR)的分子能够重定向并激活T细胞靶向肿瘤细胞,代表了一类新型且有前景的癌症生物治疗药物。使用TCR可以靶向细胞内表达且高度选择性的癌症抗原,但也需要复杂的成熟过程以提高TCR天然较低的亲和力和稳定性。尽管TCR结构域可以通过噬菌体和酵母展示进行成熟,但这些技术共同存在非人源糖基化模式的缺点,并且需要后期重新格式化为最终的双特异性形式。

在此,我们描述了在中国仓鼠卵巢(CHO)展示系统的开发和应用,用于在最终双特异性TCR形式背景下对TCR进行亲和力工程改造。基于重组酶介导的盒式交换(RCME)的系统允许将双特异性TCR分子以高效率稳定、单拷贝整合到CHO细胞的特定基因位点中。

我们使用该系统从编码靶向黑色素瘤优先表达抗原(PRAME)的模型TCR不同CDR变体的文库中分离出亲和力增加的双特异性T细胞衔接受体(TCER)分子变体。当作为可溶性蛋白表达时,所选TCER分子对PRAME阳性肿瘤细胞表现出强反应性,并伴随活化T细胞显著的细胞因子释放。所获得的数据支持使用基于CHO展示的成熟系统在最终双特异性TCER形式背景下进行TCR亲和力成熟。

展开英文摘要原文

Bispecific T cell receptor (TCR)-based molecules capable of redirecting and activating T cells towards tumor cells represent a novel and promising class of biotherapeutics for the treatment of cancer. Usage of TCRs allows for targeting of intracellularly expressed and highly selective cancer antigens, but also requires a complex maturation process to increase the naturally low affinity and stability of TCRs.

Even though TCR domains can be matured via phage and yeast display, these techniques share the disadvantages of non-human glycosylation patterns and the need for a later reformatting into the final bispecific format.

Here, we describe the development and application of a Chinese Hamster Ovary (CHO) display for affinity engineering of TCRs in the context of the final bispecific TCR format. The recombinase-mediated cassette exchange (RCME)-based system allows for stable, single-copy integration of bispecific TCR molecules with high efficiency into a defined genetic locus of CHO cells.

We used the system to isolate affinity-increased variants of bispecific T cell engaging receptor (TCER) molecules from a library encoding different CDR variants of a model TCR targeting preferentially expressed antigen in melanoma (PRAME).

When expressed as a soluble protein, the selected TCER molecules exhibited strong reactivity against PRAME-positive tumor cells associated with a pronounced cytokine release from activated T cells. The obtained data support the usage of the CHO display-based maturation system for TCR affinity maturation in the context of the final bispecific TCER format.

论文信息

作者
Dilchert J、Hofmann M、Unverdorben F、Kontermann R、Bunk S
单位
Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15, 72076 Tuebingen, Germany.Germany
期刊
Antibodies (Basel, Switzerland)2022 May 10
原文标识
PubMed 35645207 · DOI 10.3390/antib11020034